MA29256B1 - Composes pharmaceutiques - Google Patents

Composes pharmaceutiques

Info

Publication number
MA29256B1
MA29256B1 MA30146A MA30146A MA29256B1 MA 29256 B1 MA29256 B1 MA 29256B1 MA 30146 A MA30146 A MA 30146A MA 30146 A MA30146 A MA 30146A MA 29256 B1 MA29256 B1 MA 29256B1
Authority
MA
Morocco
Prior art keywords
acid
dichloro
relates
carboxylic acid
benzoylamino
Prior art date
Application number
MA30146A
Other languages
English (en)
Inventor
Paul Graham Wyatt
David Charles Rees
Mladen Vinkovic
Gary Trewartha
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0501475A external-priority patent/GB0501475D0/en
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of MA29256B1 publication Critical patent/MA29256B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'INVENTION CONCERNE UN SEL D'AJOUT D'ACIDE DE PIPÉRIDINE-4-YLAMIDE ACIDE DE 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIQUE ET DES CRISTAUX DE CELUI-CI. CE SEL EST CONSTITUÉ D'UN ACIDE SÉLECTIONNÉ DANS LE GROUPE COMPRENANT DE L'ACIDE MÉTHANESULFONIQUE ET DE L'ACIDE ACÉTIQUE, AINSI QUE DES MÉLANGES DE CEUX-CI. L'INVENTION CONCERNE ÉGALEMENT DE NOUVELLES UTILISATIONS DE SELS DE PIPÉRIDINE-4-YLAMIDE D'ACIDE 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIQUE. L'INVENTION CONCERNE ENCORE DES PROCÉDÉS POUR LA PRÉPARATION DE PIPÉRIDINE-4-YLAMIDE 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIQUE ET DE SES SELS, AINSI QUE DE NOUVEAUX INTERMÉDIAIRES CHIMIQUES.
MA30146A 2005-01-21 2007-08-16 Composes pharmaceutiques MA29256B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64597305P 2005-01-21 2005-01-21
GB0501475A GB0501475D0 (en) 2005-01-22 2005-01-22 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
MA29256B1 true MA29256B1 (fr) 2008-02-01

Family

ID=36129898

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30146A MA29256B1 (fr) 2005-01-21 2007-08-16 Composes pharmaceutiques

Country Status (18)

Country Link
US (2) US8013163B2 (fr)
EP (1) EP1846393B1 (fr)
JP (1) JP5184892B2 (fr)
KR (1) KR101344691B1 (fr)
AR (1) AR054425A1 (fr)
AU (1) AU2006207323B2 (fr)
BR (1) BRPI0606594A2 (fr)
CA (1) CA2593560C (fr)
IL (1) IL184504A (fr)
MA (1) MA29256B1 (fr)
MX (1) MX2007008783A (fr)
NO (1) NO340738B1 (fr)
NZ (1) NZ556471A (fr)
PE (2) PE20061018A1 (fr)
RU (1) RU2410385C2 (fr)
SA (1) SA06260465B1 (fr)
TN (1) TNSN07277A1 (fr)
WO (1) WO2006077426A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256106B1 (fr) 2003-07-22 2015-05-06 Astex Therapeutics Limited Composes 1H-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (CDK) et modulateurs de la glycogene synthase kinase-3 (GSK-3)
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
EP1845973B1 (fr) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Composes pharmaceutiques
WO2006077425A1 (fr) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinaisons d'inhibiteurs de pyrazole kinase et d'autres agents antitumoraux
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
EP1845974A1 (fr) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Composes pharmaceutiques
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
CN101133088B (zh) * 2005-03-03 2011-04-13 三菱丽阳株式会社 聚合物粒子、含有它的树脂组合物、成型体
CN101193862B (zh) 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
CA2651152A1 (fr) * 2006-05-05 2007-11-15 Astex Therapeutics Limited (1-methanesulfonyl-piperidin-4-yl)-amide de l'acide 4-(2,6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylique pour le traitement du cancer
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
WO2008007123A2 (fr) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Composés pharmaceutiques
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) * 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
ES2548578T3 (es) 2007-12-27 2015-10-19 Kissei Pharmaceutical Co., Ltd. Monosebacato de un derivado de pirazol
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
WO2017161253A1 (fr) * 2016-03-18 2017-09-21 Tufts Medical Center Compositions et méthodes de traitement et de prévention de troubles métaboliques
BR112019003722A2 (pt) 2016-08-23 2019-05-28 Eisai R&D Man Co Ltd terapias de combinação para o tratamento de carcinoma hepatocelular
WO2018170447A1 (fr) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Polythérapies pour le traitement du cancer du sein

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917432A (en) 1954-10-05 1959-12-15 Burroughs Wellcome Co Leukemia treatment
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
GB1354939A (en) 1971-10-28 1974-06-05 Ici Ltd Process for the manufacture of 1,1,2-triphenylalk-1-enes
US4005063A (en) 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
DE2845574A1 (de) 1978-10-19 1980-04-24 Deutsches Krebsforsch Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
JPS6425763A (en) * 1987-04-24 1989-01-27 Mitsubishi Chem Ind Pyrazoles and insecticide and acaricide containing said pyrazoles as active ingredient
US5164196A (en) 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5002755A (en) 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
JPH05507480A (ja) 1990-05-26 1993-10-28 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 医薬品抵抗性の克服の際に使用するための１，４―ジヒドロピリジン
IL100110A0 (en) 1990-12-26 1992-08-18 American Cyanamid Co Insecticidal and synergistic miticidal compositions
HU219131B (hu) 1991-10-18 2001-02-28 Monsanto Co. Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
DK0674624T3 (da) 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CA2203517A1 (fr) 1994-11-10 1996-05-23 Alan M. Laibelman Compositions pharmaceutiques a base de pyrazole, agissant comme inhibiteurs des proteines kinases
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
WO1997027852A1 (fr) * 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibiteurs de la farnesyle transferase
JP2000509371A (ja) 1996-04-03 2000-07-25 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
WO1997036897A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
EP0904076A1 (fr) 1996-04-03 1999-03-31 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
JP4426650B2 (ja) 1996-05-03 2010-03-03 アボット・ラボラトリーズ 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
DE69728986T2 (de) 1996-06-21 2005-04-07 Allergan, Inc., Irvine Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
CA2275796A1 (fr) 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Composes heteroaromatiques contenant de l'azote, utilises en tant qu'inhibiteurs du facteur xa
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2288910C (fr) 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones pour des dysfonctions sexuelles
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
HRP980334A2 (en) 1997-06-19 1999-04-30 Mimi Lifen Quan INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
CA2314401A1 (fr) 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Heteroaromatiques contenant de l'azote, presentant des groupes p1 a substitution ortho, et utilises en tant qu'inhibiteurs du facteur xa
WO1999067235A1 (fr) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Co., Ltd. Composes cycliques a cinq elements
JP2000186092A (ja) 1998-12-22 2000-07-04 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１の製造法
WO2000038683A1 (fr) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company INHIBITEURS DU FACTEUR Xa OU DE LA THROMBINE
CA2368630A1 (fr) 1999-04-02 2000-10-12 Ruth R. Wexler Sulfonyles aryles faisant office d'inhibiteurs du facteur xa
CA2366932C (fr) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Inhibiteurs cycliques de proteine tyrosine kinase
US6166244A (en) 1999-05-07 2000-12-26 Allergan Sales, Inc. Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity
AU5283600A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
WO2001014331A2 (fr) 1999-08-24 2001-03-01 Regents Of The University Of California Inhibiteurs exempts de quinoline de parasites du paludisme
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CZ2002961A3 (cs) * 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
US6485907B1 (en) 2000-01-11 2002-11-26 Syngenta Participations Ag PCR-based detection of Rhizoctonia cerealis
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
WO2001064642A2 (fr) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides et inhibiteurs connexes du facteur xa
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
WO2001081345A1 (fr) 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Composes d'amides aromatiques
JP2004509064A (ja) 2000-04-27 2004-03-25 アボット・ラボラトリーズ 置換フェニルファルネシルトランスフェラーゼ阻害剤
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
HUP0302966A2 (hu) 2000-07-31 2003-12-29 Smithkline Beecham P.L.C. Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DZ3398A1 (fr) 2000-08-31 2002-03-07 Pfizer Prod Inc Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001212168A1 (en) 2000-10-20 2002-05-06 Bristol-Myers Squibb Pharma Company Acylsemicarbazides and their use as cyclin dependent kinase (CDK) inhibitors
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
DE10064823A1 (de) 2000-12-22 2002-06-27 Knoll Ag Integrinrezeptorliganden
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0102687D0 (en) * 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
JP2004530659A (ja) 2001-02-28 2004-10-07 ジャイルズ，ブライアン，シー． 抗腫瘍および抗転移作用のための方法および処方
AU2002254107B2 (en) 2001-03-05 2006-12-21 E. I. Du Pont De Nemours And Company Heterocyclic diamide invertebrate pest control agents
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
CA2436911A1 (fr) 2001-03-16 2002-09-26 Pfizer Inc. Composes pyrazolo[4,3-d]pyrimidinone en tant qu'inhibiteurs de gmpc pde
WO2002074298A1 (fr) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
KR20100008794A (ko) 2001-04-16 2010-01-26 쉐링 코포레이션 Ｃｘｃ-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
RU2332415C2 (ru) * 2001-04-27 2008-08-27 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, полезные в качестве ингибиторов протеинкиназы
WO2002092002A2 (fr) 2001-05-11 2002-11-21 The Burnham Institute Methodes de criblage, methodes diagnostiques et therapeutiques relatives a riz
WO2002094183A2 (fr) 2001-05-18 2002-11-28 Tap Pharmaceutical Products Inc. Methode de traitement d'une tumeur, utilisant des derives de fumagillol
BR0209912A (pt) 2001-05-21 2004-04-06 Du Pont Composto, método de controle de pragas invertebradas e composição para controle das mesmas
AU2002312370A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Antipathogenic benzamide compounds
WO2003011287A1 (fr) 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Derives de pyrazole comme inhibiteurs de gsk-3
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
JP2005507875A (ja) 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なピラゾール類似体
CA2465978C (fr) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibiteurs de l'histone-deacetylase
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
WO2003040147A1 (fr) 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Composes heteroaryles substitues azabicycliques pour le traitement de maladies
WO2003048081A2 (fr) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides en tant qu'inhibiteurs du facteur xa
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
US7205307B2 (en) 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
MXPA04008577A (es) 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
EP1485093B1 (fr) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Modulateurs de tetrazole di-aryle substitues du recepteur 5 de glutamate metabotropique
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
WO2004026867A2 (fr) 2002-09-19 2004-04-01 Schering Corporation Nouvelles imidazopyridines utilisees comme inhibiteurs des kinases dependantes des cyclines
WO2004039795A2 (fr) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Composes amide
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004099127A1 (fr) 2003-05-07 2004-11-18 Novo Nordisk A/S Composes utilises comme inhibiteurs de kinase
EP1625115A1 (fr) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Derives pyrimidiques substitues
WO2005000309A2 (fr) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Composes chimiques
WO2005000356A1 (fr) 2003-06-27 2005-01-06 Ono Pharmaceutical Co., Ltd. Remede contre des maladies des voies urinaires
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP2256106B1 (fr) 2003-07-22 2015-05-06 Astex Therapeutics Limited Composes 1H-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (CDK) et modulateurs de la glycogene synthase kinase-3 (GSK-3)
SE0303396D0 (sv) 2003-12-16 2003-12-16 Astrazeneca Ab Chemical compounds
EP1718306A2 (fr) 2004-02-20 2006-11-08 Chiron Corporation Modulation de processus inflammatoires et metastatiques
US7842820B2 (en) 2004-03-11 2010-11-30 4Sc Ag Sulfonylpyrroles
US20060084691A1 (en) 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
EP1845974A1 (fr) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Composes pharmaceutiques
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006077425A1 (fr) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinaisons d'inhibiteurs de pyrazole kinase et d'autres agents antitumoraux
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
EP1845973B1 (fr) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Composes pharmaceutiques
EP1847531A4 (fr) 2005-02-09 2009-04-22 Takeda Pharmaceutical Derive de pyrazole
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
CA2651152A1 (fr) 2006-05-05 2007-11-15 Astex Therapeutics Limited (1-methanesulfonyl-piperidin-4-yl)-amide de l'acide 4-(2,6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylique pour le traitement du cancer
US20090142337A1 (en) 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
JP2009543770A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
WO2008007123A2 (fr) 2006-07-14 2008-01-17 Astex Therapeutics Limited Composés pharmaceutiques
EP2049106A2 (fr) 2006-07-14 2009-04-22 Astex Therapeutics Limited Combinaisons pharmaceutiques
EP2046327A1 (fr) 2006-07-21 2009-04-15 Astex Therapeutics Limited Utilisation médicale d'inhibiteurs de kinases dépendants de la cycline
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations

Also Published As

Publication number Publication date
IL184504A0 (en) 2007-10-31
AU2006207323B2 (en) 2012-06-07
TNSN07277A1 (en) 2008-12-31
NO340738B1 (no) 2017-06-06
PE20061018A1 (es) 2006-10-31
US8293767B2 (en) 2012-10-23
US20090012124A1 (en) 2009-01-08
US20110274616A1 (en) 2011-11-10
CA2593560C (fr) 2014-12-09
EP1846393B1 (fr) 2020-02-19
KR101344691B1 (ko) 2013-12-26
IL184504A (en) 2015-10-29
AU2006207323A1 (en) 2006-07-27
AR054425A1 (es) 2007-06-27
NZ556471A (en) 2010-12-24
WO2006077426A3 (fr) 2006-09-28
CA2593560A1 (fr) 2006-07-27
EP1846393A2 (fr) 2007-10-24
BRPI0606594A2 (pt) 2009-07-07
RU2007131100A (ru) 2009-02-27
SA06260465B1 (ar) 2010-06-20
NO20073957L (no) 2007-10-12
PE20091785A1 (es) 2009-12-16
JP5184892B2 (ja) 2013-04-17
JP2008528470A (ja) 2008-07-31
WO2006077426A2 (fr) 2006-07-27
MX2007008783A (es) 2007-09-11
RU2410385C2 (ru) 2011-01-27
US8013163B2 (en) 2011-09-06
KR20070107050A (ko) 2007-11-06

Similar Documents

Publication Publication Date Title
ECSP055910A (es) Nuevos acidos carboxilicos y sus esteres, medicamentos que contienen estos compuestos y procedimientos para su preparacion
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
TN2009000138A1 (fr) Biaryl-ether-urees
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
EP1592689A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
WO2007070434A3 (fr) Amino-piperidines fusionnees en tant qu'inhibiteurs de la dipeptidyl peptidase-4 pour le traitement ou la prevention du diabete
NO20022095L (no) Heterocyklisk substituerte pyrazoloner
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
MA29652B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
TNSN07277A1 (en) Pharmaceutical compounds
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
ATE396190T1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
MA29311B1 (fr) Derives d'isoxazolines et son nouveau procede de production
WO2006017836A3 (fr) Nouveaux derives de 2-amino-quinazoline utiles en tant qu'inhibiteurs de la $g(b)-secretase (bace)
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
EA200601065A1 (ru) Производные имидазола, способы их получения и применения
NO20076405L (no) Anvendelse av 24-nor-UDCA
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater